drugset / Trial / NCT03767257

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257

Phase 2 Completed 25 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of colesevelam and find out what effects, if any, colesevelam has on lenalidomide associated diarrhea in participants with multiple myeloma on lenalidomide maintenance.

Timeline

Start
2018-12-03
Primary completion
2024-11-27
Completion
2024-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified 1250 mg